Terms: = Ovarian cancer AND MNX1, HB9, 3110, ENSG00000130675, P50219, HLXB9 AND Treatment
4 results:
1. Comprehensive network analysis of dysregulated genes revealed mnx1-AS1/hsa-miR-4697-3p/HOXB13 axis in ovarian cancer chemotherapy response.
Wu A; Liu J; Zhang X; Niu C; Shu G; Yin G
Cancer Sci; 2022 Aug; 113(8):2627-2641. PubMed ID: 35639251
[TBL] [Abstract] [Full Text] [Related]
2. LncRNA mnx1-AS1 promotes ovarian cancer process via targeting the miR-744-5p/SOX12 axis.
Shen Y; Lv M; Fang Y; Lu J; Wu Y
J Ovarian Res; 2021 Nov; 14(1):161. PubMed ID: 34789303
[TBL] [Abstract] [Full Text] [Related]
3. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
Harrison RF; Fu S; Sun CC; Zhao H; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2021 Jul; 225(1):68.e1-68.e11. PubMed ID: 33549538
[TBL] [Abstract] [Full Text] [Related]
4. Half-dose bevacizumab experience in relapsed ovarian cancer patients in Turkey due to formal regulations: similar effectiveness with lower rate of hypertension.
Kose F; Alemdaroglu S; Mertsoylu H; Besen AA; Guler OC; Simsek SY; Erbay G; Onal C; Celik H
J BUON; 2020; 25(4):1928-1934. PubMed ID: 33099934
[TBL] [Abstract] [Full Text] [Related]
